CalciMedica reports 62.7% relative mortality reduction with Auxora in AKI subset of CARDEA trial

CalciMedica, Inc.

In patients with AKI (eGFR ≤60) plus respiratory failure, Auxora reduced day-30 mortality by 62.7% vs placebo; 17.4% vs 46.7% died.
Absolute mortality reduction of 29.3% in AKI subset; full study showed 56.3% relative reduction (p=0.017) with 9.9% absolute reduction.
Preclinical and biomarker data supporting CRAC channel inhibition in AKI were also presented.
Ongoing Phase 2 KOURAGE trial in Stage 2/3 AKI with hypoxemic respiratory failure is expected to read out in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.